What is this event about?
![Pain](http://www.SAE Media Group-online.co.uk/_media/graphics/Fotolia_2735596_M.jpg) |
SAE Media Group ran its first conference on pain therapeutics in 2001, and has run a highly successful conference on this topic every year since. In 2010, our industry-leading Pain Therapeutics conference returns for its tenth year, and will build on the knowledge-base and reputation that SAE Media Group has in this area to deliver the most interesting and informative conference yet.
Taking place in London, UK, this conference will look at a wide range of issues withing the pain therapeutics arena. It will combine a study of the latest successes in the research and development phase with presentations covering the key themes of biomarkers and the cannabinoid approach.
Questions examined during the conference will include: Do cannabinoid medicines have a place in our pain arsenal? How do regulatory authorities treat emerging clinical development biomarkers. What are the latest targets being researched? How do we treat associated conditions for chronic pain? How effective is translational research for pain measurement? Attend this event to discover the latest success stories in researching and marketing pain therapeutics.
Fancy speaking at the conference? Do you know of anyone who may be interested in speaking? We are always on the look-out for new speakers for our upcoming conferences. Let us know: SAE Media Groupproduction@SAE Media Group-online.co.uk.
For sponsorship and exhibitioning opportunities, contact sponsorshipdept@SAE Media Group-online.co.uk
|
Why should you attend this event?
Delegates at this conference will learn about
- The latest successes and failures for new targets and drugs
- The use and regulation of biomarkers for early drug development
- The cannabinoid approach to pain therapeutics
- Animal models and translational approaches
- Options and pitfalls in early drug development
- Biologics for the treatment of pain
|
![Pain 2](http://www.SAE Media Group-online.co.uk/_media/graphics/doctor with x-ray.jpg) |
![Pain medication](http://www.SAE Media Group-online.co.uk/_media/graphics/755990_25381750.jpg) |
How you will benefit from attending this conference
Hear from some of the most important and influential experts working in pain therapeutics
Learn
Conference agenda
Welcome and introductions Preclinical translational biomarkers - can they make a difference?
Kristina Holmberg, Team Leader, Pfizer
Translational challenges in analgesia
Karin Hygge Blakeman, Team Leader, AstraZeneca
Chairman's opening remarks Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford Regulatory challenges for new neuropathic pain therapeutics Jeffrey Tobias, Chief Medical Officer, NeurogesX
Regulatory issues related to neuropathic pain product approvals
Differences between the USA and the EU regulatory perspectives
Innovative solutions utilised for recent approvals of Qutenza® in the EU and USA
The use of quantitative human pain biomarkers in early drug development Lars Arendt-Nielsen, Director, Centre for Sensory-Motor Interaction, Aalborg University
Advanced mechanism-based human pain biomarkers
Human proof-of-concept studies in analgesic drug development
Pain mechanism based target validation
Translational neurophysiological biomarkers of peripheral nerve function Martin Koltzenburg, Chair of Clinical Neurophysiology and Deputy Director, Centre for Neuromuscular Disease
Ion channels in peripheral nerves as a target for novel analgesic drugs and prevention of neuropathies
Nerve excitability testing provides a novel translational tool to examine non-invasively the function of different ion channel classes, including voltage-gated sodium channels and potassium channels
Drugs affect these excitability parameters differentially and allow direct assessment of target engagement
Discovery of TRPV1 antagonists for pain management: Issues and opportunities Arthur Gomtsyan, Associate Research Fellow, Neuroscience and Pain Research, Abbott Laboratories
Discovery of Abbott TRPV1 antagonist clinical candidate
Chemistry and preclinical pharmacology
Temperature effects of TRPV3 antagonists
Predictive validity of animal models for analgesia - what's ahead? Odd-Geir Berge, Senior Principal Scientist, AstraZeneca
Where are we with current models?
Future choices - Black-box or mechanistic modelling?
Emerging approaches
Pain modulation and transmission at cannabinoid receptors Aldemar Degroot, Associate Scientific Director, Exploratory Development Department, Astellas
The cannabinoid receptors and pain
Agonists
Endocannabinoids
Recent developments
Future prospects
Does chromatin or epigenetic modification offer an alternative approach to the treatment of chronic, clinical pain states? Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford
What is epigenetics?
Role of environment and stress
Evidence in pain and inflammation
Potential pitfalls
Regulation of endogenous analgesia by the endocannabinoid system: sites and mechanisms of action David Finn, Co-Director, Centre for Pain Research, National University of Ireland, Galway
Role of the endocannabinoid system in stress-induced analgesia
Activity in supraspinal components of the descending inhibitory pain pathway
Neurochemical and molecular mechanisms
Chairman's closing remarks and close of day one Re-registration and coffee Chairman's opening remarks Tim Young, Associate Research Fellow, Pfizer Targeting the endocannabinoid system for pain Tim Young, Associate Research Fellow, Pfizer
The challenges of agonist development
Modulation of endocannabinoid tone
Future perspectives
Options and pitfalls in early drug development Wia Timmerman, Project Leader, Pain/fMRI Research Initiative, TI Pharma
Experimental pain models in healthy volunteers
Phenotyping of patients with chronic pain using quantitative sensory testing
Healthy volunteer models and patient studies: potential for fMRI
Challenges in preclinical pain research Isabel Gonzalez, Head of Biology, Proximagen Neuroscience
Why work on pain research
Current animal models
The way forward
Preclinical ion channel targets for next generation analgesics Steve England, Associate Research Fellow, Pfizer
Progress with isoform-selective voltage-gated sodium channel modulators
The ups and downs of TRP channels
Emerging targets
Advances in the development of TRPA1 ligands - pharmacology and future directions Adrian Mogg, Research Scientist - Pain-Migraine DHT, Eli Lilly
Introduction to the TRP super-family
Preclinical rationale for TRPA1
Pharmacology and insights
Efficacy in vivo
Future directions
The use of Laser Doppler Flowmetry (LDF) to measure cutaneous blood flow in rats: a potential translational biomarker for clinical pain studies Sharon Bingham, In Vivo Pharmacology & Translational Science, GlaxoSmithKline
What measurement of cutaneous blood flow can tell us about pain mechanisms: target engagement vs. surrogate end points
Optimisation and validation of a preclinical model of electrically evoked changes in blood flow using Laser Doppler Flowmetry
Advantages of this technique from an ethical perspective: the 3Rs
Prostanoid EP4 receptor antagonists as novel pain therapeutics Karen Maubach, Group Manager of Project Management, BTG
Pivotal role of EP4 receptor in both pain and inflammation
Latest evidence from pre-clinical and experimental medicine models
EP4 receptor antagonists offer potential to be effective and better tolerated analgesics
Pharmacological characterisation of a new sigma-1 receptor antagonist for the treatment of neuropathic pain José Miguel Vela, Basic Research & Drug Discovery, Esteve
Sigma-1 receptors play a key role in modulating activity-induced sensitisation in nociceptive pathways and are thus a new potential target of action for drugs designed to alleviate neuropathic pain
A new and selective sigma-1 receptor antagonist (S1RA) has been developed by Esteve that inhibits neuropathic pain behaviours in rodents
Safety and efficacy data support S1RA as a new therapeutic agent for the treatment of neuropathic pain
Human clinical trials are ongoing
Chairman's closing remarks and close of conference
Workshops
Crowne Plaza - The City 9 June 2010 London, United Kingdom
VENUE
Crowne Plaza - The City
19 New Bridge Road, London, United Kingdom
A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM
copyright ©
2024
SAE Media Group
|